Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma.

Gynecologic oncology - 1 Sept 2015

Jones Nathaniel L, Xiu Joanne, Reddy Sandeep K, Burke William M, Tergas Ana I, Wright Jason D, Hou June Y

Abstract excerpt

BACKGROUND: Therapeutic options are limited for uterine serous carcinoma (USC). TP53, PIK3CA, FBXW7, and ERBB mutations, as well as HER2 and EGFR overexpression have been reported. We aim to evaluate patterns of molecular, genomic and protein changes in 628USC tumors. METHODS: 628 consecutive cases of USC submitted to Caris Life Sciences from Mar, 2011 to July, 2014 were reviewed. These were analyzed using the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cohort Studies
Share to Cystadenocarcinoma, Serous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to DNA Mutational Analysis

Share to Immunohistochemistry

Share to In Situ Hybridization, Fluorescence

Share to Molecular Targeted Therapy

Share to Uterine Neoplasms

Source

Identifiers

PMID: 26123645
DOI: 10.1016/j.ygyno.2015.06.034

Genes

PTEN
BRCA1
BRCA2
CISH
EGFR
ERCC1
KRAS
MGMT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma.PMID 26123645Read ↗

Updates in therapy for uterine serous carcinomaSemantic proximity Read ↗

Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.Semantic proximity Read ↗

Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.Semantic proximity Read ↗

Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.Semantic proximity Read ↗

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.Semantic proximity Read ↗

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.Semantic proximity Read ↗

Germline mutations of the DNA repair pathways in uterine serous carcinoma.Semantic proximity Read ↗

Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.Semantic proximity Read ↗

Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma.Semantic proximity Read ↗

Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assaysSemantic proximity Read ↗

Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.Semantic proximity Read ↗

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.